Table 1.

Hypertension treat-to-target randomized controlled trials (mean age > 70 y)

TRIAL	POPULATION STUDIED	AGE RANGE (MEAN), Y	TARGET SBP, MM HG	ACHIEVED MEAN BP, MM HG	PRIMARY OUTCOME AND COMMENTS
JATOS¹ (N = 2418)	Japanese patients with SBP ≥ 160 mm Hg	65–85 (74)	Treatment: < 140 Control: 140–159	136/75 vs 146/78	No benefit on primary composite outcome of CV events or renal dysfunction after 2-y follow-up Used a long-acting CCB (efonidipine) as base of therapy
VALISH² (N = 3260)	Japanese patients with ISH (SBP 160–199 mm Hg)	70–84 (76)	Treatment: < 140 Control: 140–149	137/75 vs 142/77	No benefit on primary composite outcome of CV events or renal dysfunction after 3.1-y follow-up Used an ARB (valsartan) as base of therapy
ACCORD-BP³ (N = 4733)	Patients with T2DM with high risk of CV disease	40–79 (62)	Treatment: < 120 Control: < 140	119.3 vs 133.5	No difference in primary outcome of CV events after 4.7-y follow-up Some decrease in stroke, but increase in adverse events Trial was randomized and controlled but not blinded

ACCORD-BP—Action to Control Cardiovascular Risk in Diabetes–Blood Pressure, ARB—angiotensin receptor blocker, BP—blood pressure, CCB—calcium channel blocker, CV—cardiovascular, ISH—isolated systolic hypertension, JATOS—Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients, SBP—systolic blood pressure, T2DM—type 2 diabetes mellitus, VALISH—Valsartan in Elderly Isolated Systolic Hypertension.